
Ronny Allan
This topic comes up regularly on patient forums, twitter, Facebook….. in fact everywhere! Personally, I don’t tend to get too excited about it, although there can be extremes. Most people (not all) are just stumped to know exactly what to say. Even as a person with cancer, I sometimes feel awkward when faced with someone I just found out has a serious illness. It’s really difficult to know what to say, knowing how they might react and it’s particularly difficult if you don’t really know the person, for example on social media, you could be talking to someone who you have never met, you don’t know anything about them; and they may not even speak English as a first language (those who have tried google/twitter or Facebook translator, will know it’s not perfect!).
I’ve dabbled in this arena before with my blogs “I look well but you should see my insides” and “You must be doing OK, you’ve not had chemotherapy”.
This video was produced by BBC and shared by my friends in Macmillan Cancer Support, and it’s getting a huge number of comments and opinions. Someone suggested it should have been entitled “Things to say to someone with cancer” and there’s something in that I guess – although I suspect it’s just as difficult!
Personally, I think there’s no right or wrong answer. However, I know a lot of you guys will enjoy the video
Thanks for reading
You may also enjoy these similar and related articles:
Things not to say to a cancer patient – click here
Shame on you! – click here
I look well but you should see my insides – click here
Things are not always how they seem – click here
Not every illness is visible – click here
Not the stereotypical picture of sick – click here
An Ode to Invisible Illness – click here
Poker Face or Cancer Card – click here
I don’t look sick, sorry not sorry – click here
Dear Doctors – there’s no such thing as a good cancer – click here
You must be doing OK; you’ve not had chemotherapy – click here
Top 10 Posts & Pages in the last 48 hours (auto updates) (Click the titles to read them)
Thanks for reading.
I’m also active on Facebook. Like my page for even more news. Help me build up my new site here – click here and ‘Like’
Sign up for my newsletters – Click Here
My Diagnosis and Treatment History
Check out my online presentations
Check out my WEGO Health Awards
Like my new awareness page – click here or on the photo. (Like rather than follow please!)
Check out my Glossary of Terms – click here
Please Share this post for Neuroendocrine Cancer awareness and to help another patient
My 12 lockdown episodes
In the first update of this series, I explained that I kept my diary going, but again, only on my public Facebook page, so I was prompted to document these on my blog site to cater for those not on Facebook who only see what I produce in blog format. But it’s my intention to also post these on my other public Facebook sites. Because I was self-isolating, Chris was also isolating under the rules and she was also feeling under the weather. During our self-isolation period, the government ordered a “lock-down” (a bit like the shelter-in-place term used in USA) but out of self-isolation, we were still allowed out for some exercise and other essential trips such as doctors’ appointments and shopping for essential items.
The second update is a nice walk to a local beauty spot and back.
The third update is a potpourri of events including hair issues, a broken tooth and my first COVID lockdown injection covering 14/15 Apr 2020.
The fourth update is a story of bikes, ponies, wisteria and Vitamin D covering 16th – 21st Apr 2020.
The fifth update is a story of greenery, sun, adventure and Irrfan
The sixth update is a story of footpath etiquette, sheep, donkeys and dopamine covering 30th Apr – 3rd May 2020.
The seventh update is a story of swans, cycling, VE Day and my 124th monthly cancer treatment covering the period 6th – 11th May 2020.
The eighth update is a story of nurses, trees and Canada covering the period 12th – 17th May 2020.
The ninth update is a story of cream teas, peaks and blue sky covering the period 18th – 23rd May 2020.
The tenth update is a story of the Wall, Swans, Dundee and New Forest History, covering the period 26th – 29th May 2020.
The eleventh update is a story of Walking the Wall, coping strategies and the London Ga68 PET, covering the period 30th May – 5th June 2020.
The twelfth update is a story of surviving, cycling, Scottish holiday memories including the ‘Fairy Pools’, covering the period 7th – 15th June 2020.
A
- Abdomen
- Ablation
- Abscess
- ACE inhibitor
- Achlorhydria
- Acid reflux
- Acromegaly
- Actin
- Acute
- Ac-225
- Addison's disease
- Adenocarcinoma
- Adenoma
- Adhesions
- Adjunctive therapy
- Adjuvant surgery
- Adjuvant therapy
- Adrenaline
- Adrenal cortex
- Adrenal glands
- Adrenal insufficiency
- Adrenal medulla
- Adrenocortical Carcinoma (ACC)
- Adrenocorticotropic Hormone (ACTH)
- Advanced neuroendocrine cancer
- AdVince
- Afinitor
- Aggressive
- Albumin
- Alcohol
- Alcohol flushing reaction
- ALDH2
- Aldosterone
- Allergies
- Alopecia
- alt
- Alternative medicine
- Alternative therapies
- American Society of Clinical Oncology (ASCO)
- Amines
- Amino acids
- Amoxicillin
- Ampulla
- Ampulla of Vater
- Amylase
- Analogue (US Analog)
- Anaphylactic shock
- Anaplastic
- Anastomosis
- Androgrens
- Anemia
- Anesthesia
- Aneurysm
- Angiogenesis
- Angiogenesis inhibitor
- Angiogram
- Angioma
- Anorexia
- Anterior
- Antiacids
- Antibiotics
- Antibody
- Anticoagulant
- Antidepressant
- Antiemetic agent
- Antigen
- Antihistamines
- Antineoplastic therapy
- Antioxident
- Anti-angiogenic therapy
- Anxiety
- Aorta
- Apoptosis
- Appendectomy
- Appendiceal NET
- Appendix
- Apudoma
- Aretha Franklin
- Arrhymia
- Arterial embolization
- Ascending colon
- Ascites
- Aspiration
- Assay
- Asthma
- ASTX727
- Ataxia
- Atezolizumab (Tecentriq)
- Atopic dermatitis
- Atrophic gastritis
- ATRX
- Atypical
- Atypical carcinoid tumour
- Atypical Lung NET
- Autosomal dominant
- Avelumab (Bavencio)
- Avistan
- Axid (Nizatidine)
- Axilla
- Axillary nodes
- AZEDRA
B
- BAM
- Barium enema
- Barium swallow
- Barrett's Esophagus
- Bavencio
- Benign
- Benign NET
- Benign tumour
- Beta emitter
- Bevacizumab
- Bias
- Biased agonist
- Bile
- Bile acids
- Bile acid diarrhea
- Bile acid malabsorption
- Bile acid sequestrant
- Bile duct
- Bile salt
- Biliary
- Biliary tract cancer
- Bilirubin
- Bioavailable
- Biofeedback
- Biogenic amines
- Biological therapy
- Biomarker
- Biopsy
- Bland liver embolization
- Blinded study
- Blood area nitrogen (BUN)
- Blood brain barrier (BBB)
- Blood cells
- Blood clot
- Blood count
- Blood glucose
- Blood test
- Blood thinner
- Blue Book
- Blushing
- Bolus
- Bone marrow
- Bone marrow biopsy and aspiration
- Bone marrow suppression
- Bone metastases
- Bone scan
- Bowel
- Bowel cancer
- Bowel obstruction
- Bowel surgery
- Bradykinin
- Brain serotonin
- Brain tumour
- Breast cancer
- Breast NEN
- Broken capillaries
- Bronchi
- Bronchial
- Bronchial NET
- Bronchiole
- Bronchitis
- Bronchopulmonary Neuroendocrine Neoplasms (BP NEN)
- Bronchoscopy
- Bronchus
- BUN
- Butt dart
- Bynfezia Pen
- Bypass
- B12
- B3
C
- Cabometyx
- Cabozantinib
- Cachexia
- Calcitonin
- Calcitonin gene-related peptide (CGRP)
- Calcium
- Calorie
- CAM
- Camera pill
- Cancer
- Cancerous tumour
- Cancerversary
- Cancer anger
- Cancer causes
- Cancer grading
- Cancer of unknown primary (CUP)
- Cancer registries
- Cancer related fatigue
- Cancer research
- Cancer staging
- Cancer surveillance
- Cancer survivor
- Cancer vaccine
- Candidiasis
- Capecitabine
- CAPecitabine TEMozolomide (CAPTEM).
- Capecitabine (Xeloda)
- Capsule endoscopy
- CAPTEM
- Carbocaine
- Carbohydrate
- Carboplatin
- Carcinogen
- Carcinoid
- Carcinoid crisis
- Carcinoid heart disease
- Carcinoid rage
- Carcinoid syndrome
- Carcinoid tumour
- Carcinoma
- Cardiopulmonary hemodynamic instability
- Carney-Stratakis syndrome (CSS)
- CAR-T
- Catecholamines
- CA 19-9
- CA-125
- CA4P
- CB-839
- CDKN1B
- Cerebellum
- Chemotherapy
- Chemo bath
- Chinese dumplings
- Cholangiocarcinoma
- Cholecalciferol
- Cholecystectomy
- Cholestyramine
- Chromaffin cells
- Chromogranin
- Chromogranin A (CgA)
- Chromogranin B (CgB)
- Chromogranin C (CgC)
- Chronic condition
- Cimetidine
- Cisplatin
- Cisplatin/Etoposide
- CLARINET
- Clexane
- Clinical trial
- CLO test
- Cobalamin
- Coeliac disease
- Cognitive behavioural therapies (CBT)
- Colonoscopy
- Colony stimulating factor-1 receptor (CSF-1R)
- Colon cancer
- Colon NET
- Colorectal cancer
- Combined Neuroendocrine Carcinoma
- Combretastatin A-4 phosphate (CA4P)
- Cometriq
- Comorbidity
- COMPETE trial
- Complete blood count (CBC)
- Complex regional pain syndrome (CRPS)
- Constipation
- CONTROLNETS
- Core Biopsy
- Coronavirus
- Corticotrophin releasing hormone (CRH)
- Cortisol
- COR-003
- COR-005
- COVID-19
- Creon
- CRN00808
- CRN01941
- Crohn's Disease
- Cryoablation
- CT enterography
- CT guided aspiration
- CT scan
- Curative surgery
- Cure
- Cushing's disease
- Cushing's syndrome
- Cyberchondria
- Cyberknife
- Cytoreductive
- Cytotoxic
- C cell
- C-peptide
- C‑Reactive Protein (CRP)
D
- dailyprompt
- dailyprompt-1879
- DAXX
- Debulking surgery
- Degenerative bone disease
- Depression
- Dermal fibrosis
- Dermatitis
- Desmoplasia
- Detectnet
- DEXA scan
- Dexilent
- Dexlansoprazole
- Diabetes
- Diagnosis
- Diarrhea
- Diet
- Differential diagnosis
- Differentiation
- Diffuse hepatic steatosis
- Digestive enzymes
- DIPNECH
- Distal pancreatectomy
- Distant metastatis
- Distributive shock
- Diverticulitis
- DNA
- DNA methylation-based profiling
- Doctor Google (Dr. Google)
- Dopamine
- Dopamine receptors
- Dostarlimab
- DOTA-NOC
- DOTA-TATE
- DOTA-TOC
- Do no harm
- DP1038
- Dry skin
- DUNE trial
- Duodenal NET (dNET)
- Duodenum
- Durvalumab
- Dysbiosis
E
- Early Diagnosis
- ECG
- Echocardiogram
- Ectopic Cushing’s syndrome (ECS)
- Eczema
- Edotreotide
- EGFR
- EKG
- Electrolytes
- ELECT study
- Eliquis (apixaban)
- EMA
- Endocrine
- Endocrine function (pancreas)
- EndolucinBeta
- Endoscopic retrograde cholangiopancreatography (ERCP)
- Endoscopic ultrasound (EUS)
- Endoscopy
- ENETS
- Enterade® advanced oncology formula
- Enterochromaffin cells
- Enterolith
- Enucleation
- EPAS1
- Epidemiology
- Epidermal growth factor receptor (EGFR)
- Epinephrine
- Epi pens
- Erythematotelangiectatic rosacea (ETR)
- Erythrocyte sedimentation rate (ESR)
- Esomeprazole magnesium
- Essiac therapy (Essiac tea)
- Estrogen
- Ethanol
- Etoposide
- EUS
- Everolimus
- Exocrine cells
- Exocrine function (pancreas)
- Exocrine pancreatic insufficiency
- Explorer PET scan
- External beam radiotherapy
F
- False negative
- False positive
- Familial medullary thyroid cancer (FMTC)
- Familial NET
- Famotidine
- Fasting Gut Endocrine Profile
- Fatigue
- Fatty liver
- Fat malabsorption
- Fat soluble vitamins
- FCarboSt
- Fecal bile acid test
- Fecal elastase test
- Fecal fat
- FH
- Fibre
- Fibroblast growth factor receptor (FGFR)
- Fight or flight
- Fine needle aspiration (FNA)
- Fluorine-18
- Fluoropyrimidine
- Fluorouracil (5-FU)
- Fluoro-18-L-Dihydroxyphenylalanine
- Flushing
- Focal fatty sparing
- FODMAP
- FOLFIRI
- FOLFOX
- Follicular cell
- Food allergy
- Food and Drug Administration
- Foregut
- Fosbretabulin tromethamine
- Fructose intolerance
- Full blood count (FBC)
- Full remission
- Functional tumour
G
- Gallbladder
- Gallium 68 (Ga68)
- Gamma camera
- Gamma knife
- Gastric NET
- Gastrin
- Gastrinoma
- Gastrin pH
- Gastroenterologist
- Gastroesophageal reflux disease (GERD)
- Gastrointestinal NET (GI-NET)
- Gastroscopy
- Gastro-entero-pancreatic neuroendocrine tumour (GEP-NET)
- Ga68 PET/CT
- Ga68-DOTANOC
- Ga68-DOTATATE
- Ga68-DOTATOC
- Ga68-DOTA-JR11
- Ga68-FAPI PET/CT
- Ga68-OPS202
- Generator (radionuclide)
- Generic drugs
- Genetics
- Genetic testing
- Genito-urinary NET
- Germline genetic mutations
- Gerson therapy
- Glioma
- Gliomablastoma
- Glucagon
- Glucagonoma
- Glucose (cancer sugar myth)
- Glycated Hemoglobin (A1C)
- Goitre
- Gonadotropin-releasing hormone (GnRH)
- Grade
- Grading
- Granulinoma
- Graves’ disease
- Green tea
- Ground glass opacities
- Growth hormone (GH)
- Gut
- Gut Flora
- G protein-coupled receptors (GPCR)
H
- Haemangioblastoma
- Haemoglobin (hemoglobin)
- Hashimoto's disease
- HbA1c
- Head and Neck Cancer
- Heart disease
- Heat intolerance
- Hedinger syndrome
- Helicobacter pylori
- Hemangioma
- Hemoglobin
- Hepatic arterial embolization
- Hereditary cancer syndrome
- Hereditary pheochromocytoma/paraganglioma syndromes
- High Grade NEC
- High grade neuroendocrine neoplasm (NEN)
- High grade neuroendocrine tumour (NET)
- High Residue Diet
- High-intensity focused ultrasound (HIFU)
- Hindgut
- HIPEC
- Histamine
- Histotripsy
- Hodgkin lymphoma
- Hormonal crisis
- Hormones
- Hormone therapy
- Hospice care
- Hotspot
- HPA axis
- Hurthle cell neoplasm
- Hydrocele
- Hydrocelectomy
- Hydrogen breath test
- Hydronephrosis
- Hyperadrenergic
- Hypercalcemia
- Hypercortisolism
- Hypergastrinemia
- Hyperglycemia
- Hyperhidrosis
- Hyperinsulinism
- Hyperparathyroidism
- Hypertension
- Hyperthermic intraperitoneal chemotherapy (HIPEC)
- Hyperthryroidism
- Hypervascularity
- Hypocortisolism
- Hypoglycemia
- Hypokalemia
- Hypotension
- Hypothalamus
- Hypothyroidism
- H2 blockers
- H2 receptor antagonist (H2RA)
I
- IBS
- IBS-C
- IBS-D
- IBS-M
- Ileocecal resection
- Ileum
- Immunotherapy
- Imodium
- Incidence
- Incidentaloma
- Incidental diagnosis
- Incomplete emptying
- Incurable cancer
- Indium 111-pentetreotide
- Inflammatory bowel disease (IBD)
- Inherited Cancer
- Insulin
- Insulinoma
- Insulin-like growth factor 1 (IGF-1)
- Interferon alpha (IFNα)
- Intermediate grade NET
- International Classification of Diseases for Oncology (ICD-O)
- International Classification of Diseases (ICD)
- Intestinal ischaemia
- Intraoperative chemotherapy
- Intraoperative hypertensive crisis
- Intraoperative radiotherapy (IORT)
- Invisible illness
- Iobenguane I 131
- Ipilimumab (Yervoy)
- Irinotecan (Campto)
- Iron Deficiency Anaemia
- Irreversible electroporation (IRE)
- Irritable bowel syndrome (IBS)
- Islet cell
- Islet of Langerhams
L
- Lactose intolerance
- Lactulose
- Laetrile (amygdalin or vitamin B17)
- Lanreotide
- Lansoprazole
- Laparoscopic surgery
- Large cell neuroendocrine carcinoma (LCNEC)
- Larotrectinib sulfate
- Late Diagnosis
- Lenvatinib (Lenvima)
- Lenvima
- Leukaemia (US Leukemia)
- Levoketoconazole (Recorlev)
- Levothyroxine
- Lipase
- Liquid biopsy
- Liver
- Liver cyst
- Liver directed therapy
- Liver embolization
- Liver lesion
- Liver metastases
- Loperamide hydrochloride
- Low Grade NETs
- Low residue diet
- lung
- Lung Cancer
- Lung NETs
- Lung nodules
- Lutathera
- Luteinizing hormone (LH)
- LUTIA clinical trial
- Lu 177 dotatate
- Lu-177
- Lymphadenectomy
- Lymphatic system
- Lymphedema
- Lymphoma
- Lymph nodes
M
- Magnetic resonance imaging (MRI) scan
- Malabsorption
- Malignant
- Mammalian Target of Rapamycin (mTOR)
- Mammalian target of rapamycin (mTOR) inhibitor
- Mammogram
- MANEC
- Marcaine
- Mastocytosis
- Mast cell
- MDH2
- Medical food
- Medicines and Healthcare Products Regulatory Agency
- Medicines and Healthcare products Regulatory Agency (MHRA)
- Medullary thyroid cancer (MTC)
- Melanoma
- Melatonin
- Meningioma
- Menopause
- MENX
- MEN1 syndrome
- MEN2A syndrome
- MEN2B syndrome
- MEN2 syndrome
- MEN4 syndrome
- Merkel cell carcinoma
- Mesenteric root
- Mesentery
- Metanephrines
- Metasasis
- Metastatic Neuroendocrine Cancer
- Metronidazole
- MIBG scan
- Microsatellite instability-high (MSI-H)
- Midgut
- Mineral
- Misdiagnosis
- Mitotic count
- Mitotic rate
- Mixed Neuroendocrine Non-Neuroendocrine Neoplasms (MiNEN)
- Molecular markers
- Monoamine oxidase inhibitors (MAOIs)
- Monoclonal antibodies
- MTD201
- mTOR inhibitor
- Multidisciplinary team (MDT)
- Multikinase inhibitor
- Multimodal treatment
- Multiple Endocrine Neoplasia (MEN)
- Multiple myeloma
- Multi tyrosine kinase inhibitors (TKIs)
- Mushrooms
- MYCAPSSA
- Myeloma
N
- NanoKnife®
- Naproxen
- National Cancer Institute
- National Institutes of Health
- National Institute for Health and Care Excellence (NICE)
- Nausea
- Neoplasm
- Netazepide
- NETDetect
- NETest
- NETSPOT
- NETTER-1
- NETTER-2
- NET Cancer Day
- NET Centre of Excellence
- NET syndromes
- Neuroblastoma
- Neuroendocrine
- Neuroendocrine cancer
- Neuroendocrine carcinoma (NEC)
- Neuroendocrine neoplasm (NEN)
- Neuroendocrine tumour (NET)
- Neurofibromatosis type 1 (NF1)
- Neurokinin A (NKA)
- Neurologic paraneoplastic syndromes
- Neuropeptide K
- Neurotensin
- Neurotransmitter
- Nexium
- NF1
- NHS
- Niacin
- Night sweat
- Nivolumab (Opdivo)
- Nizatidine
- NKA
- Nodule
- Noid
- Non-functional tumour
- Non-small cell lung cancer (NSCLC)
- Noradrenaline
- Norepinephrine
- North American Neuroendocrine Tumor Society (NANETS)
- Novocaine
- No evidence of disease (NED)
- No-Carrier-Added Lutetium-177 (n.c.a. Lu177)
- NT-proBNP
- Nuclear medicine
- Nutrition
- Nutrizym
O
- Octreoscan (Octreotide scan)
- Octreotide
- Octreotide scan
- Octreotide soak
- Octreotide (Octreotide acetate)
- Octreotide-RP
- Octreo-ratiopharm®
- Ocular Rosacea
- Olaparib
- Olatuton®
- Omega 3
- Omeprazole
- Omeprazole and sodium bicarbonate
- Oncologist
- Oncolytic virus
- ONC201
- Ondansetron (Zofron)
- Opdivo (Nivolumab)
- Osteoblastic activity
- Osteoporosis
- Ovarian cancer
- Ovarian NEN
- Overactive thyroid
- Overdiagnosis
- Oxaliplatin (Eloxatin)
- Oxitriptan
- Oxytocin
P
- Paclitaxel (Taxol)
- Palliative care
- Palliative treatment
- Palpitation
- Pancreas
- Pancrease
- Pancreastatin
- Pancreatic adenocarcinoma
- Pancreatic cancer
- Pancreatic cyst
- Pancreatic enzyme replacement therapy (PERT)
- Pancreatic insufficiency
- Pancreatic NET (PanNET)
- Pancreatic polypeptide (PP)
- Pancreatic pseudocyst
- Pancreatic uncinate process
- Pancreatin
- Pancreatogenic diabetes
- Pancreoprivic diabetes
- Pancrex
- Pantoloc control
- Pantoprazole
- Papillary thyroid cancer
- Papulopustular (acne) rosacea
- Paraganglia
- Paraganglioma
- Paraneoplastic syndromes
- Parathyroid gland
- Parathyroid hormone (PTH)
- Parathyroid NET
- Parotid gland NET
- PARP Inhibitor
- Partial remission
- Pasireotide
- Patent foramen ovale (PFO)
- Pathology
- PDR001
- PD-1/PD-L1 Inhibitors
- Pellagra
- Pembrolizumab (Keytruda)
- Pemetrexed disodium
- Pentetreotide
- PEN-221
- Pepcid (Famotidine)
- Peptide
- Peptide receptor radionuclide therapy (PRRT)
- Peripheral Serotonin
- Peritoneal carcinomatosis
- Pernicious anaemia
- PET Scan
- Pheochromocytoma
- Physician
- Physiological uptake
- Pituitary gland
- Pituitary NET (PitNET)
- PI3K inhibitor
- Plasma 5HIAA
- Platelet-derived growth factor receptor (PDGFR)
- Pleural Fibrosis
- pNET
- Poorly differentiated
- Post operative seroma
- PPoma
- PRCRT
- Prediabetes
- Pressor amines
- Prevacid (Lansoprazole)
- Prevalence
- Pre-existing condition
- Prilosec (Omeprazole)
- Probiotic
- Procaspase-activating compound-1 (PAC-1)
- Prognosis
- Progressive cancer
- Proinsulin
- Proliferative rate
- Prostaglandin
- Prostate Cancer
- Protease
- Proteasome inhibitors
- Protein kinase inhibitor
- Protonix (Pantoprazole)
- Proton beam therapy
- Proton pump inhibitors (PPI)
- PRRT
- Pruritus
- Pseudomyxoma peritonei (PMP)
- Pulmonary embolism
- Pulmonary fibrosis
- Pustule
- PV-10
R
- Rabeprazole (Aciphex)
- RADIANT
- Radiation therapy
- Radioactive iodine
- Radioembolization
- Radioimmunotherapy
- Radiolabelled somatostatin analogue
- Radioligand
- Radioligand therapy
- Radionuclide
- Radiopeptide
- Radiotherapy
- Radio Frequency Ablation (RFA)
- Ranitidine (Zantac)
- Rash
- RB1
- RECORLEV (levoketoconazole)
- Rectal cancer
- Rectal NET
- Red blood count (RBC)
- Remission
- Renal cell carcinoma (RCC)
- Renal insufficiency
- Residue (food)
- RET
- Retroperitoneal Fibrosis
- Retroperitoneum
- Rhinophyma
- Right hemicolectomy
- Rosacea
- Rose Bengal
S
- Sandostatin
- Sapanisertib
- SARTATE™
- Satoreotide (Lutetium-177 OPS-201)
- SB NET
- Scan
- Scanxiety
- SCF node
- Scleroderma
- SDHA
- SDHAF2
- SDHAF2(SDH5)
- SDHB
- SDHC
- SDHD
- Secretogranin II
- SEER
- Selective Internal Radiotherapy (SIRT)
- Selective Serotonin Reuptake Inhibitor (SSRI)
- Serotonin
- Serotonin and norepinephrine reuptake inhibitor (SNRI)
- Serotonin syndrome
- Serum ferritin
- Serum serotonin
- Serum 7αC4 test
- Setrons
- Side effect
- Siegfried Oberndorfer
- Sigmoidoscopy
- SIGNIFOR® (Pasireotide)
- SI NET
- Skin NET
- Sleep hyperhidrosis
- Small cell lung cancer (SCLC)
- Small cell neuroendocrine carcinoma (SCNEC)
- Small intestine bacterial overgrowth (SIBO)
- Small intestine NET (SI NET)
- Solid tumour
- Solucin ®
- SomaKit TOC
- Somatoprim
- Somatostatin
- Somatostatinoma
- Somatostatin analogues
- Somatostatin receptors (SSTR)
- Somatostatin receptor scintigraphy (SRS)
- Somatuline Autogel (US: depot)
- SOM230
- Spartalizumab
- SPECT
- Spider Veins
- SPINET
- Splenosis
- Splenunculus
- Squamous cell carcinoma
- SSTR-PET
- Stable cancer
- Stage
- Standardised uptake value (SUV)
- Steatorrhea
- Stem Cell
- Stereotactic body radiotherapy (SBRT)
- Stereotactic radiosurgery (SRS)
- Sternoclavicular joint
- Stomach cancer
- Stomach cramp
- Stomach ulcer
- Streptozotocin (Zanosar)
- Stress
- St. John's wort
- Subpectoral lymph node
- Substance K
- Substance P
- Succinate Dehydrogenase Subunit Genes (SDHx)
- Sulfatinib
- Sunitinib (Sutent)
- Superior mesenteric artery
- Superior mesenteric vein
- Supplements
- Supraclavicularfossa
- Supraclavicularfossa (SCF) lymph nodes
- Surgeon
- Surgery
- Surufatinib
- SurVaxM
- Surveillance
- Survivin
- Survivor
- Survivorship
- Sweating
- Sweet's syndrome
- Symptom
- Syndrome
- Syndrome of inappropriate antidiuretic hormone secretion (SIADH)
T
- Tachycardia
- Tachykinin
- Tagamet
- Talazoparib
- Targeted alpha-emitter therapy (TAT)
- Targeted therapy
- TAS-102
- Tecentriq (Atezolizumab)
- Technetium-99m (Tc-99m)
- Telangiectasia
- Telotristat ethyl (Xermelo)
- Temozolomide (Temodal)
- Teratoma
- Terminal cancer
- Terminal ileum
- Testicular cancer
- Testosterone
- Tetracycline
- Theranostics
- The 5 E's
- Thorson-Bioerck syndrome
- Thymic NEN
- Thyroid
- Thyroiditis
- Thyroid cancer
- Thyroid NET
- Thyroid nodule
- Thyroid stimulating hormone (TSH)
- Thyroxine (T4)
- Tidutamab
- TNM staging system
- TOCscan®
- Total gastrectomy
- Total pancreatectomy
- TPH1
- TPH2
- TP53
- Transarterial chemo embolization (TACE)
- Transarterial embolizaton (TAE)
- Transarterial radioembolization (TARE)
- Travel with Ronny
- Triapine
- Tricyclic antidepressant
- Triglycerides
- Triiodothyronine (T3)
- Tryptophan
- Tryptophan hydroxylase (TPH)
- Tuberous sclerosis (TSC)
- Tumor board
- Tumour marker
- Tumour mutational burden (TMB)
- Tumour (Tumor)
- Type 1 diabetes
- Type 2 diabetes
- Type 3c diabetes
- Type 3c diabetes mellitus (T3cDM)
- Typical lung NET
- Tyramine
- Tyrosine kinase inhibitor (TKI)
V
- Vaccine
- Vanillylmandelic acid (VMA)
- Vascular
- Vascular disrupting agent (VDA)
- Vascular endothelial growth factor (VEGF)
- Vasoactive amines
- Vasoactive intestinal peptide (VIP)
- Vasoactive peptides
- Vasodilation
- Vepesid)
- Verner-Morrison syndrome
- Vertebral haemangioma
- Vimovo
- VIPoma
- Vitamin A
- Vitamin ADEK
- Vitamin B complex
- Vitamin B1
- Vitamin B12
- Vitamin B2
- Vitamin B3
- Vitamin B5
- Vitamin B6
- Vitamin B7
- Vitamin B9
- Vitamin C
- Vitamin D
- Vitamin E
- Vitamin K
- VMT-𝛼-NET
- Von Hippel-Lindau (VHL) Syndrome
- Von Recklinghausen's disease
W
#
- 111In-DTPA-D-Phe1
- 123I-Metaiodobenzylguanidine (mIBG)
- 131I-Metaiodobenzylguanidine (mIBG)
- 177Lu OPS 201
- 177Lu-DOTA-EB-TATE
- 177Lu-DOTA-LM3
- 177Lu-Edotreotide (Solucin®)
- 177Lu-PSMA-R2
- 18F-FDG
- 18F-FDG PET/CT
- 18F-FDOPA
- 212Pb
- 212Pb-AR-RMX
- 212Pb-AR-RMX
- 225Ac
- 24-hour urinary catacholamines and metanephrines
- 3D conformal radiation therapy
- 5-Fluorouracil (5-FU)
- 5-HIAA
- 5-HT
- 5-HTP
- 5-HT3
- 5-HT3-RA
- 5-Hydrotryptophan (5-HTP)
- 5-Hydroxyindoleacetic Acid (5-HIAA)
- 5-Hydroxytryptamine (5-HT)
- 64Cu-DOTATATE
- 64Cu-SARTATE
- 67Cu-SARTATE
- 68Ga edotreotide (TOCscan®)
- 68Ga-PSMA-R2
- 75Se-homocholic acid taurine (75SeHCAT)
HI.. My mother was diagnosed with NET of the rectum in 10/2017. She had chemo and radiation and she was able to have surgery and a permanent colostomy. She did really good for about 4 months. We found out it moved to the liver. She did chemo again and was going to have the tumors removed from the liver but was unable to due to too many small ones when the surgeon saw the liver. She does have lesions on the spine and hip bone now and we just found out a small lesion to the brain. She is in the hospital with weight loss, memory problems, and weakness. She had a recent fall and broke her pelvis bone. This moves very fast and it’s just been a little over a year. I am very worried now and would like some answers about maybe how long I have left with my mother. I would like to plan some fun things for her if she has the strength…Thank you…Beth
https://polldaddy.com/js/rating/rating.js
So sorry to hear about your mother. It’s very difficult for me to answer that question. I’m not a doctor. It’s actually quite difficult for a doctor but that would be my advice if you wanted the most accurate attempt. The grade of the tumour is important when looking at these things. Do fun things with her now, it might help see her through this difficlt period. Ask your doctors about PRRT (Lutathera), it might help. Thinking of you guys today.
Hi Ronnie. I’m freaked out at the moment! It s thought I have NET mets I my eye!!! Ever heard of it. By the way I live in Canberra Australia.
Sorry to hear that Sue. I have had at least one person contact me around 1-2 years ago. It is an unusual place but I can see case studies of it online. Firstly impression of the case studies is that it is treatable. Do you have a NET experienced doctor? Just out of curiosity, where is your primary and other metastasis?